Dermira, Inc. (NASDAQ:DERM) insider Eugene A. Bauer sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 11th. The shares were sold at an average price of $30.04, for a total transaction of $225,300.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Shares of Dermira, Inc. (DERM) traded down 1.36% on Friday, reaching $29.03. 331,330 shares of the company’s stock were exchanged. The firm’s market capitalization is $1.21 billion. The firm has a 50 day moving average of $26.10 and a 200 day moving average of $28.44. Dermira, Inc. has a one year low of $21.35 and a one year high of $38.75.

Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.04). The company had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $1.00 million. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. On average, equities research analysts predict that Dermira, Inc. will post ($4.20) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/dermira-inc-derm-insider-eugene-a-bauer-sells-7500-shares-of-stock/1630930.html.

Several large investors have recently modified their holdings of the company. BlackRock Inc. lifted its position in shares of Dermira by 15.6% during the 2nd quarter. BlackRock Inc. now owns 3,922,253 shares of the biopharmaceutical company’s stock worth $114,294,000 after buying an additional 529,405 shares during the last quarter. Jennison Associates LLC raised its position in Dermira by 16.7% in the 2nd quarter. Jennison Associates LLC now owns 2,632,994 shares of the biopharmaceutical company’s stock valued at $76,725,000 after purchasing an additional 377,554 shares during the last quarter. Vanguard Group Inc. raised its position in Dermira by 9.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock valued at $40,735,000 after purchasing an additional 125,157 shares during the last quarter. Voya Investment Management LLC raised its position in Dermira by 61.4% in the 2nd quarter. Voya Investment Management LLC now owns 1,227,948 shares of the biopharmaceutical company’s stock valued at $35,783,000 after purchasing an additional 467,356 shares during the last quarter. Finally, State Street Corp raised its position in Dermira by 38.4% in the 2nd quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock valued at $23,946,000 after purchasing an additional 228,093 shares during the last quarter. Institutional investors and hedge funds own 97.56% of the company’s stock.

A number of research analysts have issued reports on the stock. BidaskClub upgraded shares of Dermira from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Cantor Fitzgerald assumed coverage on shares of Dermira in a research note on Thursday, June 22nd. They set an “overweight” rating and a $45.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $46.00 price target on shares of Dermira in a research note on Tuesday, July 18th. Evercore ISI assumed coverage on shares of Dermira in a research note on Thursday, June 29th. They set an “outperform” rating and a $48.00 price target on the stock. Finally, Zacks Investment Research lowered shares of Dermira from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Four equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $44.40.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.